Stay updated on Nal-Irinotecan & Nivolumab in Biliary Cancer Clinical Trial
Sign up to get notified when there's something new on the Nal-Irinotecan & Nivolumab in Biliary Cancer Clinical Trial page.

Latest updates to the Nal-Irinotecan & Nivolumab in Biliary Cancer Clinical Trial page
- Check3 days agoNo Change Detected
- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedThis reflects an update to the site/app revision number for the page display (moving from revision v3.5.2 to v3.5.3), with no indication of any content changes to the study record.SummaryDifference0.1%

- Check25 days agoChange DetectedPage revision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check53 days agoChange DetectedThe site revision label was updated to v3.5.0 and the previous label v3.4.3 was removed.SummaryDifference0.1%

- Check61 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3 on the page.SummaryDifference0.1%

- Check68 days agoChange DetectedThe two screenshots show no detectable differences in the page content. Study design, eligibility criteria, and outcome measures appear unchanged.SummaryDifference0.1%

- Check82 days agoChange DetectedAdded a Results Posted entry on 2026-02-13 detailing DLT incidence, PFS, adverse events, ORR/OS, and related time frames, and uploaded associated documents (Informed Consent Form, Protocol and SAP).SummaryDifference2%

Stay in the know with updates to Nal-Irinotecan & Nivolumab in Biliary Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nal-Irinotecan & Nivolumab in Biliary Cancer Clinical Trial page.